Wed, Apr 30, 11:14 AM (11 days ago)
**Shattuck Labs, Inc. (STTK) - 10-K/A Summary** **Company Overview:** Shattuck Labs, Inc. (STTK) filed this 10-K/A to include information required by Items 10 through 14 of Part III of Form 10-K, which was previously omitted from the Original Report. The company is a biopharmaceutical firm focused on developing immunotherapies. **Corporate Governance:** - Board Structure: Three classes with staggered three-year terms. - Committees: Audit, Compensation, and Nominating and Corporate Governance. - Code of Conduct: Establishes ethical standards for directors, officers, and employees. - Insider Trading Policies: Prohibits short-term trading, short sales, and hedging transactions. **Executive Compensation:** - Named Executive Officers (NEOs): Taylor Schreiber (CEO), Andrew Neill (CFO), Arunthathy Pandite (CMO). - 2024 Compensation: - Schreiber: $3,216,407 (Salary: $560,000, Stock Awards: $2,473,847, Other: $168,000) - Neill: $2,052,586 (Salary: $458,000, Stock Awards: $570,085, Other: $109,920) - Pandite: $1,849,361 (Salary: $498,000, Stock Awards: $468,933, Other: $119,520) **Security Ownership:** - Top Beneficial Owners (as of April 1, 2025): - Prosight Management, LP: 14.0% - Redmile Group, LLC: 11.7% - Adage Capital Partners L.P.: 9.8% - BlackRock, Inc.: 5.5% - The Vanguard Group: 5.0% - NEOs and Directors: Hold varying percentages of shares and options. **Related Party Transactions:** - Investors’ Rights Agreement: Provides registration rights to certain stockholders. - 2023 Private Placement: $19,999,998.30 from Redmile Group, LLC. - Related Person Transaction Policy: Approved by the Audit Committee. **Audit and Accountant Fees:** - KPMG LLP: Served as independent auditor since 2018. - 2024 Fees: $760,000 (Audit Fees). - Pre-Approval Policies: Audit Committee pre-approves all audit and non-audit services. **Future Outlook and Risk Factors:** - Strategic Focus: Continued research and development in immunotherapies. - Risk Factors: Dependence on key personnel, regulatory approvals, and market competition. **Financial Condition:** - Market Position: Approximately $102,096,000 market value of voting and non-voting common equity held by non-affiliates as of June 28, 2024. - Outstanding Shares: 47,899,240 as of April 1, 2025. **Conclusion:** Shattuck Labs, Inc. is focused on advancing its immunotherapies through strategic governance, executive compensation, and financial management. The company continues to navigate regulatory and market challenges while maintaining a strong corporate structure and financial oversight.